An initiative to develop menstrual blood-derived stem cells, cultured products derived from umbilical cord blood and umbilical cords, and femtech targeting women's health as new business domains, with the aim of commercialisation. The company is working to build a new business portfolio combining stem cell-related products with the women's health sector.